Down 26%! Buy this ASX 200 stock while it's dirt cheap

Bell Potter thinks this blue chip has been oversold and is in the buy zone now.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Challenger Ltd (ASX: CGF) shares had a day to forget on Tuesday.

The ASX 200 stock ended the session 9% lower at $5.58 after investors responded negatively to its half year results.

This latest decline means that the annuities company's shares are now down 26% from their 52-week high.

One leading broker believes this has created a buying opportunity for investors and is urging them to snap up Challenger shares while they are down.

A woman presenting company news to investors looks back at the camera and smiles.

Image source: Getty Images

Time to buy this ASX 200 stock

According to a note out of Bell Potter, its analysts felt Challenger delivered a solid result. They said:

Overall, we thought this was a good set of results, with 3 key positives in the operating metrics, and a negative which we see as non-cash accounting/timing issues.

The positives were as follows:

+1/ Cost control is delivering results, with costs down in absolute terms (despite inflationary pressures), and the cost/income ratio at 32.0% compared to 34.6% a year ago and a downward trend since 39.5% in H2 FY22. This contributed to an improvement in underlying results. +2/ ROE, the normalised group ROE was 11.6% up 1.2%, and ahead of target of 11.2%. This was the first time it was ahead of target since H1 FY22. +3/ Retail life annuity sales hit a record level at $583m, vs $469m a year ago (and $221m 3 years ago in H1 FY22).

The one negative which Bell Potter has identified relates to the ASX 200 stock's asset and liability experience. It said:

-1/ The asset and liability experience (below operating line) was -$149m, much in line with the -$145m last year but consensus was expecting -$24m. This was attributed to $61m of timing differences due to new business strain and AASB17 life risk accounting, $48m to lower property returns (lower valuations), and $102m attributed to lower expected returns on absolute return funds, compared to assumptions, plus other smaller movements.

Sell off was 'out of place'

Bell Potter believes that the selloff that followed the release of Challenger's results was "out of place" and that investors should take advantage of this by picking up shares. It said:

In our opinion, the share price reaction (down 9% or $350m off market cap) seems out of place and does not reflect the underlying/operating performance of the business, in terms of growth in new business, controlling costs or asset returns. The outlook statement was confident, and guidance maintained. The accounting issues are noncash, largely relate to timing and should reverse over time. Our Adjusted EPS forecast decreases by -4.8% for FY25 and by -2.2% for FY26 but increases by 4.1% for FY27. We reduce our price target 5.5% to $7.80 but maintain our BUY recommendation.

As you can see above, Bell Potter has retained its buy rating on the ASX 200 stock with a trimmed price target of $7.80. This implies potential upside of 40% for investors over the next 12 months.

In addition, a 5.1% dividend yield is expected in FY 2025, boosting the total potential return to approximately 45%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Challenger. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Morgans names 2 ASX shares to buy and 1 to accumulate

What is the broker recommending investors do with these shares?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

2 ASX 200 shares to buy ahead of anticipated rally: expert

After a 9.1% drop between 27 February and 23 March, the ASX 200 reversed course last Tuesday.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield

Major upside and a generous dividend yield could be on offer with this name.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

Is this ASX defence stock the next DroneShield?

Bell Potter thinks this stock could be the next to rocket. Let's find out why.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Broker Notes

This ASX healthcare stock could almost double in value according to Bell Potter

The broker believes this stock is making major breakthroughs.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

a miner holds his thumb up as he holds a device in his other hand.
Resources Shares

Experts name 3 ASX mining shares to buy after March sell-off

Investors took profits amid fears the fuel crisis could impact miners' production and earnings.

Read more »